Eduardo Schur

While COVID-19 has shifted some of the rules, research reveals that practice changes were already afoot for market newcomers.

As the market for specialty and generic products continues to become more competitive and pricing pressures increase, the 505(b)(2) pathway may allow companies more options to diversify their portfolios.